| 研究課題/領域番号 |
22KK0147
|
|---|
| 研究種目 |
国際共同研究加速基金(国際共同研究強化(B))
|
| 配分区分 | 基金 |
|---|
| 審査区分 |
中区分58:社会医学、看護学およびその関連分野
|
|---|
| 研究機関 | 長崎大学 |
|---|
研究代表者 |
吉田 レイミント 長崎大学, 熱帯医学研究所, 教授 (90432963)
|
|---|
| 研究分担者 |
樋泉 道子 長崎大学, 熱帯医学研究所, 准教授 (00778623)
柳原 克紀 長崎大学, 医歯薬学総合研究科(医学系), 教授 (40315239)
森内 浩幸 長崎大学, 医歯薬学総合研究科(医学系), 教授 (90315234)
|
|---|
| 研究期間 (年度) |
2022-10-07 – 2025-03-31
|
| 研究課題ステータス |
交付 (2023年度)
|
| 配分額 *注記 |
20,020千円 (直接経費: 15,400千円、間接経費: 4,620千円)
2024年度: 5,720千円 (直接経費: 4,400千円、間接経費: 1,320千円)
2023年度: 7,410千円 (直接経費: 5,700千円、間接経費: 1,710千円)
2022年度: 6,890千円 (直接経費: 5,300千円、間接経費: 1,590千円)
|
|---|
| キーワード | HBV / HDV / HCV / Genotype / Drug resistance / Hepatitis B Virus / Hepatitis C Virus / Hepatitis D Virus / incidence / genotype / drug resistant variant / Nigeria / Viral hepatitis / drug resistant / therapeutic |
|---|
| 研究開始時の研究の概要 |
DNA/RNA will be extracted from HBV and HCV positive serum samples stored at Nigeria CDC. PCR and sequencing will be performed to determine the genotype, drug resistant variants and predict optimal viral hepatitis therapeutic options. A rapid PCR based genotyping assays will be developed.
|
| 研究実績の概要 |
Data cleaning of the epidemiological database of the study subjects was conducted and draft summary analysis of the study subjects were performed. A second visit to Nigeria CDC was done to conduct viral nucleic acid extraction from additional 208 HBV samples and 109 HCV positive samples. HDV ELISA was also performed to 590 available HBV positive serum samples and 47 were positive. The nucleic acid extraction of HDV positive 47 samples were performed and the samples were transported to Nagasaki University for further molecular testing. HBV viral load testing was performed to 556 available samples. CT value equal or less than 30 were detected in 121 samples. Whole genome amplification and preS1-S PCR and sanger sequencing were conducted to these 121 samples for HBV genotyping. Currently the HBV genotyping data analysis is ongoing.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
The sample processing and testing are progressing well as planned. We plan to complete the data analysis for HBV, HDV and HCV genotyping and drug resistant gene testing. The study results will be presented at international meeting and prepare the manuscript for HBV in 2024.
|
| 今後の研究の推進方策 |
The PhD student from Nigeria will visit Nigeria again this year to complete nucleic acid extraction of the remaining samples and transport it to Nagasaki University. Drug resistant gene testing by pol gene amplification and sequencing will be done. Genotyping of the HDV and HCV positive samples will be performed.
|
